Occlusion devices are used to treat several defects and medical conditions like closing of a blood vessel, blockage, and hallow organs. They are extensively used to treat cardiac defects like blockages in coronary arteries and also widely used in gynecology, oncology, urology, neurology, and others. In cardiology, the occlusion devices are majorly used for left Atrial Appendage (LAA). According to researchers, these devices reduce the risk of stroke with AFib and can be an ideal substitute for patients who do not wish for or are unable to long term anticoagulation treatment. Threes devices are upgraded developed and approved and are expected to witness higher demand in the near future.
Among these, atrial septal occlusion devices are also prominently used. These are the implantable devices used on patients who are dealing with atrial septal flaws. They are widely used in cases of atrial septal flaws with ventricle enlargement or right atrial in order to avoid paradoxical embolism, or platypnea-orthodeoxia syndrome, or left-to-right shunting. Nonetheless, only secundum atrial septal flaws are ideal for closure with such devices. Devices that are inserted percutaneously are used with a catheter and comprises self-expanding double disk including nitinol mesh. The disks stay on both sides of the septal flaws and occlude the flaw.Major Key Players of the Occlusion Devices Market are:
Abbott, Cardinal Health, Boston Scientific Corporation, Medtronic, Edwards Lifesciences Corporation, BD, ASAHI INTECC CO., LTD., BVM Medical Limited, Acrostak Int., Cook, and others.
No comments:
Post a Comment